A new weight loss pill could lead to greater blood sugar control and weight loss for people with diabetes than the current oral GLP-1 (a pill similar to the injectable weight loss and diabetes drug Ozempic). The company producing this new GLP-1 receptor agonist pill, known as orforglipron, tested its effectiveness in over 1,500 people with type 2 diabetes across Argentina, China, Japan, Mexico, and USA. Those who took orforglipron had, on average, a greater drop in blood sugar levels than those who took semaglutide, and lost an average of 6-8% of their weight with orforglipron, compared to 4-5% with semaglutide. Around 10% of participants in the orforglipron groups stopped taking the pill due to side effects, compared to 4-5% in the semaglutide groups. Orforglipron can also be taken with or without food, unlike the currently available version which must be taken on an empty stomach.
New weight loss pill could be better than current GLP-1 pill for weight loss and blood sugar
